WeVote
Log In

Bill

Bill

SB 274

Psychoactive derivatives of CBD; Possession prohibited; criminal penalties provided for violations

2025 Regular Session Introduced by Dan Roberts

Alabama bill criminalizes possession of psychoactive CBD derivatives like delta-8, establishing penalties to regulate uncontrolled retail market of synthetic cannabinoid products.

Currently Indefinitely Postponed
#crimes&offenses
0
WeVote Research Nonpartisan
Bill Summary · SB 274

Legislative bill overview

SB 274 proposes to criminalize the possession of psychoactive derivatives of CBD (cannabidiol) in Alabama, establishing criminal penalties for violations. The bill targets synthetic or modified CBD products that produce psychoactive effects, distinguishing them from standard CBD products derived from hemp or cannabis.

Why is this important

CBD derivatives like delta-8 and delta-10 THC have become widely available in retail markets, often sold in gas stations and online despite existing in a legal gray area. This bill attempts to close that gap by explicitly prohibiting possession, which could significantly impact a growing consumer market and clarify enforcement for law enforcement agencies.

Potential points of contention

  • Definitional clarity: The bill's language around what constitutes a "psychoactive derivative" may be vague—does it include all modified CBD products or only those meeting certain potency thresholds? Testing and enforcement could be challenging.
  • Market disruption: Retailers currently selling legal delta-8 and similar products would face sudden prohibition, raising questions about existing inventory and consumer access to products many consider safer alternatives to traditional cannabis.
  • Federal-state conflict: While federally ambiguous, these products occupy a different regulatory space than Schedule I substances, creating potential conflicts with federal law and interstate commerce complications.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.